Topical Ganciclovir in Patients Receiving Penetrating Keratoplasty With Cytomegalovirus Endotheliitis

• Conditions: Cytomegalovirus Endotheliitis

• Registration Number: NCT01359995
• Lead Sponsor: National Taiwan University Hospital

Brief Summary

The purpose of this study was to evaluate the outcomes of topical ganciclovir in patients with cytomegalovirus endotheliitis receiving penetrating keratoplasty at National Taiwan University hospital.

Detailed Description

In this study, we recruit 7 immunocompetent patients with unexplained graft failures, which mimicked herpetic anterior uveitis and graft rejection initially, were diagnosed as CMV endotheliitis after aqueous tapping for CMV polymerase chain reaction (PCR). Topical ganciclovir was used to control and prevent the reactivation of CMV without systemic application and their clinical courses were presented after this treatment modality.

The purpose of this study was to evaluate the outcomes of topical ganciclovir in patients with cytomegalovirus endotheliitis receiving penetrating keratoplasty at National Taiwan University hospital.

Study Timeline

• Study Start: 2010-11
• Status Verified: 2011-05
• Study First Submitted: 2011-05-16
• Study First Submitted QC: 2011-05-23
• Last Update Submitted: 2011-05-23
• Study First Posted: 2011-05-25
• Last Update Posted: 2011-05-25
• Primary Completion: 2011-11
• Study Completion: 2011-11

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 7

Inclusion Criteria

• immunocompetent patients with positive results of the CMV PCR (polymerase chain reaction) from aqueous humor tapping receiving penetrating keratoplasty

Read More

Exclusion Criteria

• patients receiving systemic or intravitreal ganciclovir before topical ganciclovir use

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
clinical courses before and after topical ganciclovir in patients with CMV endotheliitis	participants will be monitored after receiving topical ganciclovir,an expected average of 1 year	evaluations including aqueous PCR for CMV, endothelium cell density on confocal microscopy,degree of anterior chamber inflammation..

Trial Locations

Locations (1)

National Taiwan University Hospital; 🇨🇳 Taipei, Taiwan